It has undoubtedly been a landmark year for MoleSense. Having moved to larger offices and expanded the team while also honing its strategy through the Biopôle Investment Programme (BIP), the company has made significant strides towards bringing its technology to market. Yet, for MoleSense, growth is about more than funding or headcount milestones: it’s about building a team united by ambition and committed to making a meaningful difference. We spoke with the founders and wider team about what it means to grow at MoleSense.
This year has been extremely busy for MoleSense, with the Vanguard Accelerator, BIP and more recently the move to bigger offices. Can you describe how the company has evolved this past year?
Everyone at MoleSense loves being busy, because we’re working on something that truly matters. After all, continuous monitoring of hormones and inflammatory proteins could transform reproductive health and women’s trajectories from menarche to menopause. It could help us ask questions we’ve never been able to ask before, let alone answer. The stakes are extremely high, and that’s what drives us every day. Bringing this technology to our users even one day earlier than planned is worth the sleepless nights and extra effort.
MoleSense brings together people with very different scientific and business backgrounds. What do you look for when bringing someone into the team, beyond technical expertise?
Resilience, an almost unhealthy obsession with making a real impact and a strongly held belief that we can achieve far more together than any of us could alone.
In a small company, every new hire can shape the way the company works. What behaviours or ways of working do you actively encourage as you build MoleSense’s culture?
We have people from very different backgrounds, including Americans, Latin Americans, Chinese, Middle Easterners and Europeans. They bring different cultures, values, and ways of thinking and working. Respecting these differences while also being curious and open-minded enough to embrace them is at the heart of our culture. We value everyone’s way of life and work, alongside a strong sense of ownership, the initiative to act without being asked and the independence to execute. In fact, the culture we’re building at MoleSense revolves around this combination of different backgrounds, individual ownership and shared ambition.
As MoleSense grows, how do you create opportunities for team members to take on new responsibilities and shape roles that may not have existed when they first joined?
It happens very organically. We’re all growing together with the company. An EPFL graduate pursuing academia or joining a large corporation might wait years before gaining real independence, ownership or leadership responsibilities. At MoleSense, that can start right after a three-month internship. When people genuinely believe in what they’re building and are given freedom to build it, titles stop mattering. What matters is the impact they make.
What is more difficult at this stage: finding people with the right expertise or finding people with the right mindset?
Finding people with the right mindset is definitely the biggest challenge. European universities don’t encourage ambition and entrepreneurial thinking as strongly as US institutions do. We’re constantly looking for those few graduates who have developed a hunger to achieve more and make a lasting impact. That’s why we invest heavily in young talent, offering a range of pre-master’s internships, MSc thesis projects and visiting PhD opportunities. We want to find people who believe in what we’re building, even before they graduate. In addition, mentorship is a big part of our culture. Technical skills can be learned, but ambition, curiosity, ownership and the drive to make a real difference are much harder to teach. As mentioned, finding people who share that mindset isn’t easy, but we can’t think of a better place in Europe to look than Switzerland, especially Biopôle!
‘“I have an idea” can very quickly turn into a new project here. There’s room to explore, get other people involved and see where it goes.’
At MoleSense, growth means giving people the freedom to explore and take ownership beyond the roles they were originally hired for. The team’s perspectives reflect a workplace where responsibilities evolve quickly, curiosity can turn into new projects and everyone has a tangible stake in the company’s progress.
Marilena Apostolidi, Chemical Engineer with MoleSense since April 2026, described how her role has expanded from microfluidics development to working across the entire disposable patch, from exploring materials and fabrication processes to design and testing.
‘“I have an idea” can very quickly turn into a new project here,’ she said. ‘There’s room to explore, get other people involved and see where it goes. Some of the things I’ve most enjoyed working on have come from being curious and having an open conversation with a colleague.’
Meanwhile, Dr. Javier Arturo Sánchez-López, Reproductive Biologist and Regulatory Affairs Specialist with MoleSense since May 2024, explained how he became involved in refining the company’s marketing strategy and connecting with clinical stakeholders who can support MoleSense’s mission. He described MoleSense as a ‘unique workplace that demands the best of your scientific expertise and soft abilities, while offering the freedom to perform your duties’.
Javier expressed a strong sense of purpose around bringing MoleSense’s innovation to the users who need it. Therefore, a particularly rewarding milestone for him involved connecting with a clinical expert who proactively recognised the technology’s potential and offered ‘enthusiastic support’ for its development.
‘Talking with the whole team is essential to understand what everyone is working on and where your skills can make the biggest difference in moving ideas forward’
Mattéo Meister, Biomedical Engineer, originally joined the company in May 2026 as a Software Engineer. Over time, his work on user interfaces gradually expanded into decisions on MoleSense’s brand, visual identity, conference materials, and even aspects of the device and packaging. Mattéo pointed to the general need for agility in the start-up environment, where you have to be ready to drive straight into new challenges. To swim rather than sink, communication and collaboration are critical. ‘Talking with the whole team is essential to understand what everyone is working on and where your skills can make the biggest difference in moving ideas forward,’ he said. ‘Things move fast, and decisions sometimes have to be made quickly and effectively.’
This sense of forward momentum is a particularly important part of working in femtech, a field that is ‘still sadly underdeveloped and undervalued’, as evoked by Mattéo. ‘Whenever I talk about our project, people appreciate what we are doing,’ he explained. ‘Those are the moments when I feel really proud to be part of it.
Finally, Dr Sara Caku, who has been working in transnational sciences and clinical affairs at MoleSense since August 2026, has also found opportunities to take on unexpected responsibilities. Alongside her clinical and regulatory work, she is organising MoleSense’s first hackathon in collaboration with pharma, AI and medtech partners.
Sara was keen to highlight the people behind MoleSense’s technology. ‘Sharing your day with people who are kind, smart, good at what they do and genuinely fun is special,’ she said. ‘And having a scientist explain the technology with real passion gives you a much more meaningful understanding of the whole product.’ In turn, this passion has translated into prestigious awards, such as the Swiss Excellence Product Award in 2026.